Palatin Technologies, Inc. (PTN) investor relations documents from the company's IR site: 2 presentations, 3 press releases; latest deck 2026-08-12. Read in-app with summaries. First-party data.
Download Our Corporate Presentation: Palatin Technologies targets the melanocortin system for obesity with MC4R agonists, including Vyleesi® approval and two new programs (Peptide & Oral Small Molecule) with IND
| Published | Type | Document |
|---|---|---|
| 2026-08-12 | Presentation | Download Our Corporate Presentation |
| 2026-05-29 | Presentation | Download Our Corporate Presentation |
| 2026-05-18 | Press release | Palatin to Begin Trading on Nasdaq Stock Exchange |
| 2026-05-13 | Press release | Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update |
| 2026-02-17 | Press release | Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update |
PTN overview · PTN earnings · PTN financials · PTN KPIs · PTN ownership · PTN peers · PTN filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.